The 13-Day Window: Bio-AI's April Inflection
A 38-source synthesis of the 13 days every major AI lab made a structural bet on biology, and what's actually proven versus projected.
The burning platform is $236 billion. That is the estimated US drug revenue losing patent protection between 2025 and 2030, with nearly 70 blockbuster drugs going off-exclusivity including Merck's Keytruda, BMS's Opdivo and Eliquis, and J&J's Darzalex.
Thirteen days. That is how long it took for every major AI lab to make a direct structural bet on biology in response.
Not tooling for biology. Not partnerships with pharma. Biology itself, as the primary product surface.
April 3: Anthropic acquires Coefficient Bio for roughly $400 million in stock, an eight-month-old stealth biotech with fewer than ten people, most of them former Genentech and Prescient Design computational biologists. Roughly fifty million dollars per head.
April 14: AWS launches Amazon Bio Discovery at its Life Sciences Symposium, an agentic platform giving researchers access to 40-plus biological foundation models trained on large biological datasets. Same day, Novo Nordisk signs with
This intel brief is for EP Intel subscribers
Join EP Intel for full reports, deep-dives, and exclusive briefs.
Locked: The 13-Day Window: Bio-AI's April Inflection